[CALA] Calithera Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.5 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CALA

Refresh chart

Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-8.67
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.57% ROE-21.41% ROI
Current Ratio25.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-20.47 M Cash From Operating Activities-7.63 M Gross Profit
Net Profit-7.86 M Operating Profit-7.87 M Total Assets96.87 M Total Current Assets90.31 M
Total Current Liabilities3.52 M Total Debt Total Liabilities3.77 M Total Revenue
Technical Data
High 52 week17.9 Low 52 week4.1 Last close4.28 Last change-3.93%
RSI33.33 Average true range0.26 Beta1.75 Volume180.6 K
Simple moving average 20 days-6.3% Simple moving average 50 days-13.16% Simple moving average 200 days-45.84%
Performance Data
Performance Week-2.84% Performance Month-14.5% Performance Quart-34.73% Performance Half-46.56%
Performance Year-71.31% Performance Year-to-date-48.8% Volatility daily4.31% Volatility weekly9.64%
Volatility monthly19.76% Volatility yearly68.44% Relative Volume2060.39% Average Volume384.91 K
New High New Low

News

2019-03-07 20:40:17 | Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 16:06:00 | Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

2019-03-05 07:05:00 | Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

2019-03-04 07:05:00 | Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

2019-02-27 16:35:00 | Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019

2019-02-22 08:00:00 | Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-21 16:05:00 | Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

2019-02-16 06:00:00 | Updated Results from Phase 1 Study of Telaglenastat CB-839 to be Presented at 2019 ASCO Genitourinary Cancer Symposium

2019-02-04 07:05:00 | Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat CB-839 and Everolimus in Renal Cell Carcinoma

2019-01-28 07:30:00 | Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-18 14:19:35 | What Did Calithera Biosciences, Inc.’s NASDAQ:CALA CEO Take Home Last Year?

2019-01-07 07:05:00 | Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline

2018-11-30 08:00:00 | Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference

2018-11-21 09:50:06 | Intrinsic Calculation For Calithera Biosciences Inc NASDAQ:CALA Shows Investors Are Overpaying

2018-11-09 08:10:00 | New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production

2018-11-08 07:11:14 | Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT

2018-11-07 20:35:01 | Calithera CALA Reports Q3 Loss, Lags Revenue Estimates

2018-11-07 19:32:17 | Calithera: 3Q Earnings Snapshot

2018-11-07 16:05:00 | Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-10-31 08:00:00 | Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

2018-10-15 08:55:00 | Market Trends Toward New Normal in Nasdaq, Calithera Biosciences, Pinnacle West Capital, National Instruments, American Vanguard, and American Axle & Manufacturing — Emerging Consolidated Expectations, Analyst Ratings

2018-10-05 13:06:47 | What Investors Should Know About Calithera Biosciences Inc’s NASDAQ:CALA Financial Strength

2018-10-05 07:01:00 | Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

2018-10-05 07:00:00 | Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® palbociclib and talazoparib in Combination with CB-839

2018-09-26 08:00:00 | Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

2018-09-24 08:00:00 | Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable

2018-08-29 07:05:00 | Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference

2018-08-20 15:45:12 | Edited Transcript of CALA earnings conference call or presentation 7-Aug-18 9:00pm GMT

2018-08-14 20:15:00 | Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-07 19:40:11 | Calithera CALA Reports Q2 Loss, Tops Revenue Estimates

2018-08-07 18:34:18 | Calithera: 2Q Earnings Snapshot

2018-08-07 16:08:00 | Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights

2018-08-07 15:00:00 | Calithera Biosciences, Inc. to Host Earnings Call

2018-08-01 07:00:00 | Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

2018-06-21 08:00:00 | Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks

2018-06-06 05:01:00 | Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

2018-06-04 08:01:00 | Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology ASCO

2018-05-16 07:30:00 | Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-05-10 20:35:30 | Calithera Biosciences Inc NASDAQ:CALA: Is Breakeven Near?

2018-05-10 17:56:13 | Calithera: 1Q Earnings Snapshot

2018-05-10 16:05:00 | Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights

2018-04-25 16:51:08 | Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

2018-04-25 16:03:00 | Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018

2018-04-20 07:40:00 | Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences’ CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment

2018-04-19 08:55:12 | Calithera's Kidney Cancer Candidate Gets Fast Track Status

2018-04-18 07:17:54 | Calithera Biosciences stock surges on news of FDA fast track designation for kidney cancer treatment

2018-04-18 07:01:00 | Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

2018-04-13 08:02:00 | Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018

2018-03-23 08:00:00 | Calithera to Present at Needham & Company 17th Annual Healthcare Conference

2018-03-23 00:49:23 | [$$] Dracen Pharma Grabs $36 Million Commitment from Deerfield